Go to the list of all blogs
Anna G's Avatar
published in Blogs
Feb 22, 2022
Cronos (CRON, $3.53) beats quarterly earnings expectations

Cronos (CRON, $3.53) beats quarterly earnings expectations

Cronos Group reported  its quarterly earnings that surpassed analysts’ expectations.

 The cannabis research company’s earnings came in at $0.21 per share for the quarter, beating the Zacks' consensus estimate of $0.13.  Earnings in the prior-year quarter were $0.19 a share.

Revenue rose +79.6% from the year-ago quarter to $20.40 million, compared to analysts' expectations of $23.03 million.

Cronos Group had a negative net margin of 258.59% and a negative return on equity of 9.48%.

Related Ticker: CRON

CRON in downward trend: price may drop because broke its higher Bollinger Band on June 29, 2026

CRON broke above its upper Bollinger Band on June 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In of the 42 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CRON turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Momentum Indicator moved above the 0 level on June 26, 2026. You may want to consider a long position or call options on CRON as a result. In of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CRON moved above its 50-day moving average on June 24, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CRON crossed bullishly above the 50-day moving average on June 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.957) is normal, around the industry mean (46.335). P/E Ratio (23.909) is within average values for comparable stocks, (99.034). CRON's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.679). CRON has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.036). P/S Ratio (6.596) is also within normal values, averaging (114.727).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.01B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 17%. TLPH experienced the highest price growth at 36%, while BTAI experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 43%. For the same stocks of the Industry, the average monthly volume growth was 18% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 66
Price Growth Rating: 57
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
CRON
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

pharmaceutical, medical marijuana, cannabis

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Other
Address
4491 Concession Rd 12
Phone
+1 416 504-0004
Employees
610
Web
https://www.thecronosgroup.com
Interact to see
Advertisement
An AI-driven comparison between D-Wave Quantum (QBTS) and IonQ (IONQ) points to IonQ as the stronger opportunity heading into 2026. The analysis highlights IONQ’s gate-based, trapped-ion quantum architecture, which supports a wide range of algorithms and positions the company for broader adoption across AI, simulation, and cryptography.
An AI-driven comparison of Rigetti Computing (RGTI) and D-Wave Quantum (QBTS) points to Rigetti as the more compelling opportunity heading into 2026. The analysis highlights RGTI’s gate-based quantum architecture, which supports universal quantum computing and a wide range of complex algorithms. While D-Wave remains a leader in quantum annealing for optimization problems, Rigetti’s full-stack, gate-based approach offers greater scalability and broader long-term applications.
An AI-driven comparison between Rocket Lab USA (RKLB) and Planet Labs (PL) identifies Rocket Lab as the more compelling investment heading into 2026. The analysis highlights RKLB’s vertically integrated space services and consistent launch performance, which position the company to benefit from rising demand for satellite deployment and space infrastructure.
An AI-driven comparison of UnitedHealth Group (UNH) and CVS Health (CVS) points to UnitedHealth as the stronger investment heading into 2026. The analysis emphasizes UNH’s deeply integrated healthcare model, combining insurance, data analytics, pharmacy services, and care delivery into a single ecosystem. This structure provides resilience and earnings stability in an increasingly complex healthcare environment.
SoundThinking, Inc. (SSTI), a developer of precision-policing and security technologies, has faced a difficult trading environment in recent weeks. With shares trading in the single digits, the stock reflects broader investor hesitation toward small-cap tech amid ongoing economic uncertainty. The company’s market capitalization stands near $100 million, and its valuation metrics suggest skepticism around its growth outlook.
Lionheart Holdings (CUB) has traded quietly in recent sessions, reflecting the typical behavior of a SPAC still in its pre-merger search phase. Shares have hovered close to the company’s IPO price, supported by low volatility and thin trading volumes. This pattern mirrors broader trends across the SPAC market, where investor engagement often remains subdued until a definitive acquisition agreement is announced.
Astronics Corporation has delivered solid share price performance in recent sessions, benefiting from renewed enthusiasm for aerospace and defense equities. The stock has demonstrated resilience despite broader market volatility, drawing consistent investor interest due to its exposure to mission-critical avionics, power systems, and test equipment.
Recent analyst upgrades from Piper Sandler and Morgan Stanley underscore improving valuation and renewed confidence in Motorola Solutions’ growth outlook. Third-quarter 2025 results exceeded expectations, with revenue increasing 7.8% year over year, driven by land mobile radio (LMR) and video security demand.
General Dynamics shares have remained resilient in recent sessions, continuing an upward trend despite broader market volatility. Heightened attention on global defense spending has reinforced confidence in the company’s extensive backlog and well-balanced exposure across aerospace, marine systems, combat platforms, and mission-critical technologies.
Innovative Aerosystems (ISSC) has emerged as a standout performer within the aerospace and avionics space, with its stock reflecting optimism around rising demand for advanced cockpit and navigation systems. Recent trading has seen shares hold near the upper end of their range, supported by strong fundamentals and a diversified customer base spanning business aviation, commercial airlines, and military platforms.
Hexcel Corporation (HXL), a leading supplier of advanced composite materials used across aerospace, defense, and industrial markets, has maintained steady momentum amid a shifting industry backdrop. Recent share performance reflects investor optimism around a gradual recovery in commercial aviation, balanced against concerns about production timing and cost pressures.
AAR Corp. shares have shown notable strength in recent trading, benefiting from favorable conditions in the aerospace and defense sector as global air travel continues to recover. The stock has trended higher on the back of strong fundamentals in parts distribution, maintenance, and engineering services.
TAT Technologies (TATT), a provider of aerospace and defense systems with a focus on heat transfer solutions and MRO services, has demonstrated notable strength in recent trading. Shares have climbed sharply over the past month, reflecting growing investor confidence in the company’s operational improvements and exposure to aerospace recovery trends.
The Utilities Select Sector SPDR Fund (XLU) has shown unusual volatility early in 2026. After a strong 22% gain through November 2025, fueled by AI-driven electricity demand and falling interest rates, XLU dipped to around $43 by January 7 amid broader equity pullbacks and insider selling at holdings like UGI Corporation. While utilities are typically stable, this behavior signals potential opportunities as data center electricity demand is projected to double by 2030, positioning utilities as key beneficiaries of the AI boom.
TSM’s upcoming earnings carry outsized importance for the semiconductor industry. As the world’s leading contract chip manufacturer, TSMC underpins AI innovation for customers such as Nvidia and Apple. Its results often serve as a bellwether for global chip demand, capacity constraints, and pricing trends.
Goldman Sachs (GS) is expected to report Q4 2025 EPS of $11.65 on revenue of $13.85 billion, reflecting steady results as investment banking activity continues to recover.
Citigroup (C) is expected to report Q4 2025 EPS of $1.58, representing a 17.9% year-over-year increase, with revenue projected at $20.95 billion, up 7%. Bank of America (BAC) consensus estimates call for Q4 EPS of $0.96, up from $0.82, on revenue of $27.74 billion, reflecting 9.45% growth. JPMorgan Chase (JPM) is forecast to deliver Q4 EPS of $4.86, a modest 0.95% increase, with revenue expected to rise 8.13% to $46.25 billion.
Wells Fargo (WFC) is expected to report Q4 2025 earnings on January 14, 2026, with consensus calling for EPS of $1.66, up 16.9% year over year, and revenue of approximately $21.66 billion, a 6.3% increase. Investor focus will center on net interest income stabilization, growth in fee-based businesses such as investment banking and mortgages, and credit provisioning in a lower-rate environment.
Wall Street expects Infosys Q3 FY2026 EPS of $0.20, based on estimates from eight analysts, with revenue forecast at ₹452.37 billion (approximately $5.45 billion), compiled from 33 analysts.
BitMine Immersion Technologies (BMNR) is set to report Q1 FY2026 earnings on January 16, 2026, with consensus estimates calling for EPS of $0.15 and revenue of approximately $79.3 million.